~~<i id='EC4EA0C8AA'><strike id='EC4EA0C8AA'><tt id='EC4EA0C8AA'><pre id='EC4EA0C8AA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：comprehensive 2025-09-30 11:58:41 - browse：7867

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

focus

hotspot

knowledge

explore

hotspot

AdobeAPittsburghartificialintelligencestartupemergingasachallengertoMicrosoft’sclinicalnotetakingbus

WSS

Blood tests recalled over risk of missed heart attack diagnosis

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Reporting on presidential health from Reagan to Trump and Biden

Secretariat’s lessons for human medicine

hotspot

leisure time

focus

At least 13 dead in Texas as scorching temps continue

Hospitals are piloting generative AI tools as regulators play catch

Drug repurposing or repositioning? The language matters

Blood tests recalled over risk of missed heart attack diagnosis

Sports medicine is finally prioritizing gender equality

Who gets to use the title 'doctor'?

At least 13 dead in Texas as scorching temps continue

FDA warns medical device makers about rise in fabricated data

Novavax promises a turnaround & Lilly roils the obesity market

Opioid cravings were reduced by anti

focus

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Congress: Eradicate hepatitis C and reduce the deficit

Measles policy set amid Florida outbreak alarms vaccine proponents

Can CDC director Mandy Cohen drive consensus in Washington?

Reporting on presidential health from Reagan to Trump and Biden

hotspot

knowledge

explore

hotspot